Regeneron ^Investor

Regeneron Pharmaceuticals is a leading biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. They have a diverse product portfolio that includes therapeutic candidates for the treatment of cancer, eye diseases, and inflammatory diseases. Their achievements include the development of EYLEA, an aflibercept injection, and ARCALYST, a rilonacept injection, among others. Regeneron is known for its commitment to scientific research and its dedication to bringing life-transforming medicines to patients in need. They were founded in 1988 and are headquartered in New York, USA.